SEQSTER and Antidote have revolutionized patient matching and clinical research efficiency. SEQSTER’s patient-centric healthcare platform provides a comprehensive view of medical history, genomic data, and lifestyle factors. Antidote’s patient engagement platform accelerates clinical trial recruitment.
By integrating SEQSTER’s technology, Antidote can accurately match patients to clinical trials, leveraging a holistic understanding of their health profiles. This accelerates recruitment and ensures better patient quality. Patients benefit from more precise matches to potential clinical trials for which they qualify.
Furthermore, the partnership enables real-time data access to study participant health data, streamlining the path to medical advancements. CEO and Co-Founder of SEQSTER, Ardy Arianpour, emphasizes the transformative potential of this partnership in addressing the challenges of clinical trial recruitment and participant engagement.
Samantha Veeck, Co-CEO of Antidote, highlights the importance of connecting suitable patients to the right trials, combining advanced technology with a personalized approach. Antidote’s precision recruitment process is enhanced by SEQSTER’s data integration capabilities, optimizing the identification of suitable participants and reducing the time to market for new treatments.
The partnership also promotes diversity in drug development. Providing access to patient medical records ensures better representation of underserved populations in clinical trials. This meets FDA diversity requirements and improves the generalizability of research findings.
Integrating SEQSTER’s and Antidote’s technologies simplifies patient enrollment, reducing the time to initiate clinical studies. Antidote’s focus on personalized patient services and SEQSTER’s technology enhance patient engagement, promoting adherence to trial protocols and accurate data collection. This partnership empowers researchers with the tools and insights needed for successful clinical research and the development of innovative treatments.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
